Answers are grounded in this paper and cite their sources.
This editorial highlights preliminary evidence suggesting the endothelin-A receptor gene polymorphism may be associated with reduced baroreflex sensitivity, while emphasizing the need for larger studies to confirm functional relevance.
The complex interaction between different pathogenetic mechanisms, which characterizes the development of a number of cardiovascular diseases (CVD), often does not allow the identification of their direct determinants. This is especially the case when exploring the possible role of underlying genetic factors in this context. In the attempt to reduce the distance between genes and complex phenotypes, the dissection of the genetic basis of several intermediate disease phenotypes has become an increasingly common approach over recent years [1,2]. A lower number of genes is expected to be involved in the determination of specific phenotypes that individually contribute to the whole spectrum of CVD-related phenotypic alterations. Therefore, their identification may be not only easier, but also of significant clinical interest in that it may yield useful clues for a better understanding of specific factors involved in CVD pathophysiology. Representative examples of these intermediate phenotypes in patients with CVD are the level of sympathetic activity and the sensitivity of a major mechanism involved in cardiovascular homeostasis, such as the arterial baroreflex. Indeed, alterations of both these parameters are frequently involved in the development of CVD, and have been shown to carry important prognostic information. An impairment of the arterial baroreflex has been demonstrated to play an adverse role in several cardiovascular diseases [3–7]. This is especially the case in congestive heart failure, where the impairment of baroreceptor ability to modulate sympathetic tone [8] is held partly responsible for the marked sympathetic activation that characterizes this condition [9], and may contribute to its adverse prognosis [10,11]. This is also the case for myocardial infarction in which an impaired baroreflex modulation of the heart is associated with a higher mortality rate [5–7,12–15]. Finally, baroreflex abnormalities have been described in patients with diabetes mellitus and hypertension. This contributes to the occurrence of orthostatic hypotension in the former case and the maintenance of blood pressure elevation in the latter case [3–5,16]. The clinical relevance of a baroreflex dysfunction is supported further by studies demonstrating that interventions improving baroreflex sensitivity (BRS), such as physical training [14,17] or β-adrenergic receptor blockade [3,13,18], may also improve a patient's clinical outcome [13,14]. However, whether the baroreflex dysfunction observed in these clinical conditions also has a genetic background remains a largely unexplored issue. The paper by Ormezzano et al. published in this issue of the journal [19], offers information in such a context by assessing the possible genetic determinants of not only BRS levels in normal subjects, but also the BRS dysfunction observed in patients with yet untreated essential hypertension. The existence of a genetic component contributing to between-subject differences in BRS levels has been documented in previous studies [20,21], and some of the candidate genetic determinants have been already explored in case–control association studies with interesting results. This is exemplified by the finding of a relationship of BRS with the molecular variants of the aldosterone synthase gene [22], or with the β1 subunit of the potassium channel gene [23]. Ormezzano et al. [19] set out to more broadly investigate whether the genetic determinants of several factors involved in the regulation of cardiovascular system (i.e. components of the renin–angiotensin system, components of the endothelin system and NO synthase) might also be candidate genes for BRS regulation. Their conclusion is that only the genetic polymorphism of endothelin-A receptor EDNRA/C+1222T is significantly correlated with BRS levels (in particular with the degree of the reflex increase in heart rate following spontaneous blood pressure reduction). This was the case both in healthy subjects and in patients with arterial hypertension, even after accounting for multiple confounders; the T allele of EDNRA/C+1222T polymorphism being associated with a reduction in BRS. In other words, the results of the study performed by Ormezzano et al. [19] appear to highlight the gene encoding endothelin-A receptor as the most relevant genetic contributor to BRS among all other genes tested in this regard, with a molecular variant of this gene being significantly associated with reduced BRS in subjects with either normal or high blood pressure. This observation appears to be compatible with previous evidence in favour of a role of the endothelin system in the central regulation of cardiovascular functions, including the central regulation of BRS [24]. On the other hand, the data are also compatible with the observations that the endothelin-A receptor is mostly involved in mediating the cardiac effects of endothelin [25]. An important methodological difference between the present study and previous reports on the genetic determinant of BRS is that Ormezzano et al. [19] investigated the relationship of BRS levels with the possibly related genes not only in a group of normotensive subjects, but also in a sample of hypertensive patients, and obtained the same results in both instances. This makes their observations on the link between the T allele of the EDNRA/C+1222T polymorphism and BRS dysfunction more convincing than the conclusions of other studies focusing only on a single group of subjects. However, in spite of this methodological merit and notwithstanding the originality and the pathophysiological and clinical interest of their study, the conclusions of Ormezzano et al. [19] should be interpreted with caution for several reasons. First of all, the size of the study samples was not large enough to allow a definite conclusion on a complex issue such as the genetic determination of BRS. As in the case of most positive results obtained by previous case–control association studies for several other cardiovascular phenotypes, these findings need to be confirmed through the characterization of a larger number of human subjects. A second weakness of the study, shared by most other reports on the genetic basis of BRS, is the lack of a plausible biological link between the gene polymorphism found to be associated with BRS and the phenotype itself. Precise information on a functional relevance of the specific endothelin-A receptor gene variant considered in this study is still lacking, with the only available evidence being related to its previous characterization in relation to different non-cardiovascular phenotypes such as migraine [26]. Another molecular variant of this gene has also been associated with a shorter survival time in patients affected by dilated cardiomyopathy [27], but once again in the absence of a clear demonstration of an effect of such a polymorphism on either gene expression or receptor function. Thus, in the absence of any demonstration of plausible biological relevance, the finding of a positive association between a given gene polymorphism and a specific phenotype has to be interpreted as a hypothetical disease marker only. The positive link of a gene polymorphism with the phenotype under study might not necessarily reflect its actual genetic background. Conversely, such a relationship could also be considered either as the consequence of a linkage disequilibrium, with the true disease marker located somewhere else in the gene or nearby it, or simply as the result of chance. Whereas the former explanation has to wait for the results of additional studies to be confirmed or disproved, it appears that the latter possibility can be safely ruled out in the study by Ormezzano et al. [19]. This is because of the demonstration of the same trend in both hypertensive and normotensive subjects, and because of the persistence of a positive association between the considered parameters even after multivariate analysis that accounted for the confounding effects of other non-genetic determinants of BRS. A final problem of the study by Ormezzano et al. [19] is related to the difficulty of providing a convincing explanation for the finding of an association between the genetic polymorphism of the endothelin receptor A EDNRAC/C+1222T and the sensitivity of spontaneous baroreflex control of heart rate when focusing on hypotension–tachycardia sequences only. In other words, this association was found only when considering the heart rate response to arterial baroreceptor deactivation by a blood pressure reduction and not when considering the heart rate response to arterial baroreceptor activation by a blood pressure increase. Given the complexity of arterial baroreflex control of circulation, which involves central and peripheral mechanisms (Fig. 1) and is characterized by the continuous interplay between reciprocal changes in sympathetic and in parasympathetic cardiovascular modulation [28–30], the possibility of an asymmetrical influence by genetic factors on baroreflex cardiac modulation, as suggested by the present paper needs to be confirmed in other studies.Fig. 1In conclusion, because of the difficulties outlined above with respect to data interpretation, the otherwise interesting observations made by Ormezzano et al. [19] can only be regarded as preliminary evidence. Their possible functional and clinical implications, with respect to both the molecular basis of BRS dysfunction and the pathogenetic relevance of the endothelin system in the setting of CVD, remain stimulating hypotheses waiting to be verified in future investigations of larger size.
No takes yet. Share an insight, caveat, or question.
Parati et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: